A high-performance, non-radioactive potency assay for measuring cytotoxicity: A full substitute of the chromium-release assay targeting the regulatory-compliance objective-Reference-Cited by-同舟云学术

A high-performance, non-radioactive potency assay for measuring cytotoxicity: A full substitute of the chromium-release assay targeting the regulatory-compliance objective

Published:2017-02-08 Issue:3 Volume:9 Page:521-535
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Rossignol Alexis¹,Bonnaudet Véronique¹,Clémenceau Béatrice²³,Vié Henri³,Bretaudeau Laurent¹

Affiliation:

1. Clean Cells, Boufféré, France

2. Centre Hospitalier Universitaire de Nantes, Nantes cedex 01, France

3. UMR INSERM U892, Nantes Cedex, France

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2017.1286435

Reference47 articles.

1. Recombinant therapeutic monoclonal antibodies: Mechanisms of action in relation to structural and functional duality

2. Rituximab-Dependent Cytotoxicity by Natural Killer Cells

3. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

4. Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

5. FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Label-free assessment of complement-dependent cytotoxicity of therapeutic antibodies via a whole-cell MALDI mass spectrometry bioassay;Scientific Reports;2024-09-13

2. Imaging‐Based Efficacy Evaluation of Cancer Immunotherapy in Engineered Tumor Platforms and Tumor Organoids;Advanced Healthcare Materials;2024-06-08

3. Label-free Assessment of Complement-Dependent Cytotoxicity of Therapeutic Antibodies via a Whole-Cell MALDI Mass Spectrometry Bioassay;2024-05-05

4. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in Cancer;Handbook of Cancer and Immunology;2023

5. Chronological measurement of effector CD8 T cell activity using a bioluminescence-based cell viability assay;2022-11-14